ESH ALL 2021 | Future directions for treating Ph-like ALL subtypes
Sarah Tasian
• 13 May 2021
Sarah Tasian, MD, The Children’s Hospital of Philadelphia, Philadelphia, PA, discusses where she thinks the future of treatment for ABL-class and CRLF2 JAK pathway Philadelphia-like (Ph-like) acute lymphoblastic leukemia (ALL) is heading in the coming years. Dr Tasian highlights the promising potential of combining immunotherapy and tyrosine kinase inhibitors as a possible treatment method. This interview took place during the 2021 European School of Hematology (ESH) 2nd Translational Research Conference on Acute Lymphoblastic Leukemia.
Disclosures
Dr Tasian receives/d research funding from Incyte Corporation, Beam Therapeutics, and Gilead Sciences and serves on scientific advisory boards for Aleta Biotherapeutics and Kura Oncology.
